Susquehanna International Group’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-15,206
| Closed | -$116K | – | 13451 |
|
|
2024
Q2 | $116K | Buy |
15,206
+5,012
| +49% | +$43.2K | ﹤0.01% | 10912 |
|
|
2024
Q1 | $91.7K | Buy |
+10,194
| New | +$89.6K | ﹤0.01% | 11269 |
|
|
2023
Q4 | – | Sell |
-1,120
| Closed | -$6.79K | – | 13588 |
|
|
2023
Q3 | $6.79K | Buy |
1,120
+184
| +20% | +$1.3K | ﹤0.01% | 11753 |
|
|
2023
Q2 | $6.46K | Sell |
936
-5,361
| -85% | -$35.4K | ﹤0.01% | 11807 |
|
|
2023
Q1 | $98.9K | Buy |
+6,297
| New | +$124K | ﹤0.01% | 11309 |
|
|
2022
Q4 | – | Sell |
-2,675
| Closed | -$48K | – | 14119 |
|
|
2022
Q3 | $48K | Buy |
2,675
+887
| +50% | +$19K | ﹤0.01% | 12236 |
|
|
2022
Q2 | $40K | Buy |
1,788
+1,123
| +169% | +$25K | ﹤0.01% | 12098 |
|
|
2022
Q1 | $18K | Sell |
665
-2,707
| -80% | -$98.5K | ﹤0.01% | 12656 |
|
|
2021
Q4 | $153K | Sell |
3,372
-4,065
| -55% | -$274K | ﹤0.01% | 11769 |
|
|
2021
Q3 | $620K | Sell |
7,437
-3,729
| -33% | -$308K | ﹤0.01% | 8837 |
|
|
2021
Q2 | $1.06M | Sell |
11,166
-13,914
| -55% | -$1.65M | ﹤0.01% | 7603 |
|
|
2021
Q1 | $4.17M | Buy |
25,080
+23,728
| +1,755% | +$3.14M | ﹤0.01% | 4258 |
|
|
2020
Q4 | $132K | Buy |
+1,352
| New | +$85.5K | ﹤0.01% | 10339 |
|
|
2019
Q2 | – | Sell |
-106
| Closed | -$18K | – | 10998 |
|
|
2019
Q1 | $18K | Sell |
106
-69
| -39% | -$10.3K | ﹤0.01% | 8603 |
|
|
2018
Q4 | $19K | Buy |
+175
| New | +$35K | ﹤0.01% | 8690 |
|
|
2018
Q2 | – | Sell |
-357
| Closed | -$886K | – | 10635 |
|
|
2018
Q1 | $886K | Buy |
+357
| New | +$795K | ﹤0.01% | 5508 |
|
|
2016
Q4 | – | Sell |
-40
| Closed | -$44K | – | 10315 |
|
|
2016
Q3 | $44K | Buy |
+40
| New | +$34.9K | ﹤0.01% | 8160 |
|
|
2016
Q1 | – | Sell |
-14
| Closed | -$14K | – | 9837 |
|
|
2015
Q4 | $14K | Hold |
14
| – | – | ﹤0.01% | 9264 |
|
|
2015
Q3 | $15K | Sell |
14
-1
| -7% | -$1.46K | ﹤0.01% | 9523 |
|
|
2015
Q2 | $31K | Buy |
+15
| New | +$21.3K | ﹤0.01% | 9943 |
|
|
2015
Q1 | – | Sell |
-30
| Closed | -$29.8K | – | 10063 |
|
|
2014
Q4 | $31K | Buy |
30
+8
| +36% | +$7.14K | ﹤0.01% | 9447 |
|
|
2014
Q3 | $23K | Sell |
22
-12
| -35% | -$17.7K | ﹤0.01% | 9316 |
|
|
2014
Q2 | $65K | Sell |
34
-5
| -13% | -$9.89K | ﹤0.01% | 9549 |
|
|
2014
Q1 | $83K | Sell |
39
-79
| -67% | -$197K | ﹤0.01% | 8619 |
|
|
2013
Q4 | $274K | Sell |
118
-56
| -32% | -$128K | ﹤0.01% | 7733 |
|
|
2013
Q3 | $490K | Buy |
174
+146
| +521% | +$726K | ﹤0.01% | 6457 |
|
|
2013
Q2 | $262K | Buy |
+28
| New | +$216K | ﹤0.01% | 7032 |
|
Other funds holding ONCT
PPW
QPW
VF
TRCT
Susquehanna International Group's ONCT Position: Q3 2024 in Review
Susquehanna International Group sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q3 2024, closing a stake of 15,206 shares — an estimated $116K sold.
Susquehanna International Group first reported a position in ONCT in Q2 2013 and held it in 27 quarters. The position peaked at $4.17M in Q1 2021. 23 funds tracked by Wall St. Rank hold ONCT as of Q3 2024.
- Susquehanna International Group reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
- Susquehanna International Group sold 15,206 Oncternal Therapeutics, Inc. Common Stock shares in Q3 2024, an estimated $116K.
- Susquehanna International Group first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q2 2013 and held it in 27 quarters.
- Susquehanna International Group's Oncternal Therapeutics, Inc. Common Stock position peaked at $4.17M in Q1 2021.
- 23 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q3 2024.
Based on Susquehanna International Group's 13F filing for Q3 2024, filed 14 Nov 2024.